Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
GTN (GLYCERYL TRINITRATE) SOLUTION REDUCED RESPIRATORY DISTRESS IN COVID 19 PATIENTS IF GIVEN BY NEBULIZATION
Document Type and Number:
WIPO Patent Application WO/2022/008024
Kind Code:
A2
Inventors:
AHMED MOHAMED KAMAL MOHAMED (EG)
Application Number:
PCT/EG2020/000016
Publication Date:
January 13, 2022
Filing Date:
July 06, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
AHMED MOHAMED KAMAL MOHAMED (EG)
Download PDF:
Claims:
Claims

New elements needed to protect:

1. Off - label use of gycary trinitrate (nitroglycering) who is used to treat cardiac patients mainly to treat respiratory distress syndrome (ARDS) in Covid 19 patient

2. The way (method) to use the drug nitroglycerin (glycary trinitrate) solution by the nebulizer not by infusion.

Description:
Gtn (Glyceryl Trinitrate) Solution Reduced Respiratory Distress In Covid 19 Patients If Given By Nebulization

Technical field

Problem: ARDS is series condition in sever and critical cases of Covid 19 patient Purpose: GTN (glyceryl trinitrate) solution can reduced ARDS symptoms in Covid 19patient if Given by Nabulization.

How to use (Methods):

¼ cm of GTN solution is placed in the evaporation chamber, of Nebulizer the amount determined according to the healthy condition of the patient, his weight, and the associated disease with addition to 3 cm Normal Saline. The drug is inhaled by the Nebulizer apparatus.

(Proving the effectiveness of the drug)

First: the patient was asked if he is improved or not.

Second: Place an oxymeter to measure the oxygen saturation before and after giving the solution.

Third: take and arterial blood sample and perform blood gas analysis before and after giving the solution.

Results:

Inhalation of the GTN solution by the nebulizer target the ventilated lung regions (Alveoli) lower their vascular resistance Directing blood flow to this regions and leaving the unventilated lung region.

Thus reducing shunting and Hypoxemia.

Conclusion:

GTN Solution reduced respiratory distress in Covid 19 patients if given by Nebulization. Background Art

Protocol used for treatment of Covid 19 patient is only supportive

Supportive treatment: is aimed at reliving symptoms

Till this moment no drug or vaccine present for treatment or prophylactis from a novel corona virus disease.

However many of the symptoms can be treated and therefore treatment based on the patient’s clinical condition. Moreover supportive care for infected persons can be highly effective.

The problem in the treatment of Covid 19 patient is no specific drugs or vaccines available for treatment of Covid 19 exist till now No specific antiviral treatment for Covid 19.

However, drug previously developed to treat other viril infection are being tested to see if they might also be effective against the virus that causes Covid 19.

The problems is the virus is highly adaptive reproduce so rapidly. They have planty of opportunity to mutate with each new generation potentially developing resistance to whatever drugs or vaccines we develop.

Example of drug used in treatment of Covid 19 patients

1. Hydroxyl chloroquine and chloroquine

2. Azithromycine

3. Remdisiver.

4. Tamiflu

5. Avigan

6. Convalescent. Plasma Disclosure of invention

Nitronal aqueous solution contain glycery trinitrate. 1 mg per 1 ml

Improving the respiratory distress in Covid 19 patient decrease (1 hypoxia) in mild, moderate, severe, critical patients preventing the deterioration of the condition and reach to put the patient on artificial respiratory machine if given by nebulization How to use (Methods):

¼ cm of GTN solution is placed in the evaporation chamber, of Nebulizer the amount determined according to the healthy condition of the patient, his weight, and the associated disease with addition to 3 cm Normal Saline. The drug is inhaled by the Nebulizer apparatus.

The new things is one of label use of GTN (nitroglycering) gycary trinitrate by inhalation not by infusion and use in respiratory problem not in cardiac problem as the drug known